Kengrexal
cangrelor
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Kengrexal. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Kengrexal.
For practical information about using Kengrexal, patients should read the package leaflet or contact their doctor or pharmacist.
-
List item
Kengrexal : EPAR - Summary for the public (PDF/77.11 KB)
First published: 12/06/2015
Last updated: 12/06/2015 -
-
List item
Kengrexal : EPAR - Risk-management-plan summary (PDF/183.71 KB)
First published: 12/06/2015
Last updated: 12/01/2022
Authorisation details
Product details | |
---|---|
Name |
Kengrexal
|
Agency product number |
EMEA/H/C/003773
|
Active substance |
cangrelor
|
International non-proprietary name (INN) or common name |
cangrelor
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
B01
|
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Publication details | |
---|---|
Marketing-authorisation holder |
Chiesi Farmaceutici S.p.A.
|
Revision |
15
|
Date of issue of marketing authorisation valid throughout the European Union |
23/03/2015
|
Contact address |
Via Palermo 26/A |
Product information
16/01/2023 Kengrexal - EMEA/H/C/003773 - IAIN/0030
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antithrombotic agents
Therapeutic indication
Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.